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Summary  
Weekly ixazomib with lenalidomide-dexamethasone (Rd) is feasible and has shown activity 
in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study 
(NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics, 
safety and efficacy of twice-weekly ixazomib plus Rd in NDMM; 64 patients were enrolled 
across both phases. Patients received twice-weekly oral ixazomib 3·0 or 3·7 mg plus 
lenalidomide 25 mg and dexamethasone 20 mg (10 mg in cycles 9–16) for up to sixteen 21-
day cycles, followed by maintenance with twice-weekly ixazomib alone. No dose-limiting 
toxicities were reported in cycle 1; the RP2D was 3·0 mg based on overall tolerability across 
multiple cycles. In 62 evaluable patients, the confirmed overall response rate was 94% (68% 
≥very good partial response; 24% complete response). Median progression-free survival 
was 24·9 months. Responses (median duration 36·9 months for patients receiving the 
RP2D) deepened during treatment. Grade 3 drug-related adverse events (AEs) occurred in 
64% of patients, including: rash, 13%; peripheral neuropathy, 8%; hyperglycaemia, 8%. 
There were no grade 4 drug-related AEs. Thirteen patients discontinued due to AEs. Twice-
weekly ixazomib-Rd offers substantial activity with promising long-term outcomes in NDMM 
patients but may be associated with greater toxicity compared with weekly ixazomib-Rd in 
this setting. 
 




The treatment of multiple myeloma (MM) has advanced over the past two decades with the 
introduction of proteasome inhibitors and immunomodulatory drugs, leading to improved 
survival for patients (Kumar, et al 2014a, Kumar, et al 2008). Data from phase 3 randomized 
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typically demonstrated the benefit of a triplet regimen compared with a doublet regimen, 
particularly triplet regimens containing a proteasome inhibitor (e.g., bortezomib, carfilzomib 
or ixazomib) and an immunomodulatory drug (e.g., thalidomide or lenalidomide) (Cavo, et al 
2012, Cavo, et al 2010, Durie, et al 2017, Garderet, et al 2012, Kumar, et al 2017, Moreau, 
et al 2016, Rosinol, et al 2012, Stewart, et al 2015). Additionally, early-phase studies in 
NDMM patients have demonstrated favourable tolerability and efficacy with a triplet regimen 
comprising carfilzomib plus lenalidomide and dexamethasone (KRd) (Dytfeld, et al 2014, 
Jakubowiak, et al 2012, Korde, et al 2015, Roussel, et al 2016).  
Although MM remains generally incurable despite recent treatment advances, patient 
outcomes, including progression-free survival (PFS) and overall survival (OS), have 
improved, and thanks to improved regimens and the increasing number of active treatment 
options, MM is becoming more of a chronic condition for many patients, with increasing 10-
year survival rates (Barlogie, et al 2014, Katodritou, et al 2016, Pulte, et al 2011). An 
associated development is that treatment strategies are substantially moving towards 
continuous, long-term therapeutic approaches, which have been shown to improve patient 
outcomes compared with fixed-duration therapy options (Benboubker, et al 2014, 
Guglielmelli and Palumbo 2015, Katodritou, et al 2016, Palumbo, et al 2014, Palumbo, et al 
2015). In this context, there is a need for additional active, safe and convenient regimens 
that are feasible for long-term administration, offer reduced patient burden and maintain 
quality of life (Baz, et al 2015, Delforge and Ludwig 2017, Dowling, et al 2016, Guglielmelli 
and Palumbo 2015).  
The oral proteasome inhibitor ixazomib is approved in various countries, including the 
United States and in Europe, in combination with lenalidomide and dexamethasone (Rd) for 
the treatment of patients with MM who have received at least one prior therapy. Ixazomib 
approval was based on the findings of the global, randomized, double-blind, placebo-
controlled phase 3 TOURMALINE-MM1 study (NCT01564537). In adult patients with RRMM, 
the combination of weekly ixazomib-Rd demonstrated significantly longer PFS, with limited 
additional toxicity, compared with placebo-Rd; responses to ixazomib-Rd were rapid and 
durable, deepening with increasing duration of treatment (Moreau, et al 2016). 
The triplet regimen of weekly ixazomib-Rd administered in 28-day cycles has also 
been investigated in NDMM (NCT01217957); the overall response rate (ORR) was high 
(92%), with 58% of patients achieving at least a very good partial response (VGPR). 
Responses deepened with an increasing number of treatment cycles, and the combination 
was well tolerated (Kumar, et al 2014b). Data from this study also showed the feasibility of 
long-term maintenance treatment with single-agent ixazomib (Kumar, et al 2014c). A parallel 
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dosing schedule; here, we report the findings from this study (NCT01383928) after a median 




Adult patients with NDMM (transplant eligible or ineligible) and measurable disease (defined 
as: serum M-protein ≥10 g/l, urine M-protein ≥200 mg/24 h, or involved free light chain (FLC) 
≥100 mg/l if the serum FLC ratio was abnormal), Eastern Cooperative Oncology Group 
(ECOG) performance status 0–2, and adequate renal, hepatic, cardiac and haematological 
function were eligible. Patients were excluded if they had: grade ≥2 peripheral neuropathies 
not elsewhere classified (NEC; high-level term including peripheral neuropathy [PN] and 
peripheral sensory neuropathy); major surgery or an infection necessitating antibiotics within 
14 days of commencing study treatment; prior treatment for MM; uncontrolled cardiovascular 
disorders within the past 6 months; previous deep-vein thrombosis (DVT); prolonged QT 
interval; or known human immunodeficiency virus/hepatitis infection. For detailed eligibility 
criteria see Table SI. All patients provided written, informed consent at the time of enrolment. 
 
Study design and objectives 
This open-label, multicentre (15 sites in the United States) phase 1/2 clinical trial 
(NCT01383928) was conducted in association with the Multiple Myeloma Research 
Consortium. The study was performed in accordance with the International Conference on 
Harmonisation Good Clinical Practice guidelines, the Declaration of Helsinki and appropriate 
regulatory requirements, and with approval of Institutional Review Boards at individual 
enrolling institutions.  
The phase 1 primary objective was to determine the safety, tolerability, maximum 
tolerated dose (MTD) and recommended phase 2 dose (RP2D) of twice-weekly ixazomib in 
combination with Rd. Phase 1 secondary objectives were to characterize ixazomib plasma 
pharmacokinetics in combination with Rd, and to evaluate response rates. Phase 2 primary 
objectives were to determine the combined rate of complete response (CR) plus VGPR, and 
to further evaluate tolerability and toxicity. Phase 2 secondary objectives included further 
assessment of response rates, and determination of time to response, duration of response 
(DOR), PFS and OS. 
Patients received oral ixazomib (administered on an empty stomach, ≥1 h before or 
≥2 h after a meal (Gupta, et al 2016a)) on days 1, 4, 8 and 11 of a 21-day cycle, in 
combination with oral lenalidomide 25 mg on days 1–14 and oral dexamethasone 20 mg (10 
mg in cycles 9–16) on days 1, 2, 4, 5, 8, 9, 11 and 12, for up to 16 cycles in the absence of 
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dexamethasone could be individually held or reduced in order to manage toxicities. While 
receiving Rd, all patients were required to take concurrent aspirin 81–325 mg/day (or 
enoxaparin 40 mg/day subcutaneously, or its equivalent) as anticoagulation prophylaxis. At 
the discretion of the investigator, patients could undergo stem cell collection after a minimum 
of four treatment cycles, and patients deemed transplant eligible by the treating physician 
could elect to stop treatment after a minimum of eight treatment cycles to proceed to 
autologous stem cell transplantation (ASCT) off study. Patients in both phases who were in 
response or had stable disease after 16 cycles of induction with ixazomib-Rd could proceed 
to receive maintenance therapy with single-agent ixazomib on the same schedule and at the 
last-tolerated dose during induction until disease progression or unacceptable toxicity. 
Patients who underwent ASCT did not receive ixazomib maintenance therapy post-
transplant. 
Patients were not permitted to receive concomitant systemic treatment with strong 
inhibitors of cytochrome P450 (CYP) 1A2 or strong inhibitors of CYP3A. Excluded foods and 
dietary supplements included St John’s wort and ginkgo biloba. 
 
Dose escalation and determination of the MTD and RP2D 
In phase 1, two fixed doses of ixazomib, 3·0 mg and 3·7 mg, were assessed. The starting 
dose was determined based on dose escalation in a phase 1 study of twice-weekly single-
agent ixazomib in patients with RRMM (Richardson, et al 2014), with the body surface area-
based dosing converted to fixed dosing based on results from population pharmacokinetics 
analysis (Gupta, et al 2015a). Dose escalation proceeded via a standard 3+3 scheme, 
based on dose-limiting toxicities (DLTs; see Table SII) observed in cycle 1. Patients who did 
not receive all ixazomib doses during cycle 1 for reasons other than DLTs were replaced in 
the DLT-evaluable cohort. The MTD was defined as the highest tolerated ixazomib dose at 
which no more than 1 of 6 DLT-evaluable patients experienced a DLT in cycle 1. In phase 2, 
patients received ixazomib at the RP2D, which was selected based on all available data 
from the phase 1 portion including, but not limited to: analyses of efficacy results (response 
rates: CR and VGPR) and toxicity characterization (grade 3/4 adverse events [AEs], serious 
AEs [SAEs], all-grade PN and treatment discontinuation).  
 
Assessments 
Patients were assessed for response after cycles 1, 2, 3 and 4, and then every 2 cycles 
during induction and maintenance. Responses were determined according to International 
Myeloma Working Group criteria (Durie, et al 2006, Rajkumar, et al 2011), incorporating the 
additional categories of near CR (nCR) and minimal response (MR). Bone marrow biopsy 
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disease (MRD) was assessed by flow cytometry (sensitivity of available assay: 10-4
AEs were evaluated throughout the treatment period and for 30 days after the final 
dose of study treatment and graded according to the National Cancer Institute’s Common 
Terminology Criteria for AEs, version 4·03 
(https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf). 
Patients reported their experience of neurotoxicity using the Functional Assessment of 
Cancer Therapy/Gynecology Oncology Group Neurotoxicity (FACT/GOG-Ntx) questionnaire 
(Calhoun et al 2003), which was completed on day 1 of every treatment cycle and at the 
end-of-treatment visit. 
) in bone 
marrow aspirate obtained to confirm a potential CR.  
Serial blood samples were collected during phase 1 for determination of ixazomib 
plasma pharmacokinetics (see Data SI). 
 
Statistical analysis 
Phase 1 enrolment was expected to be 12 patients. The sample size calculation for the 
phase 2 component was designed to test the null hypothesis of a CR + VGPR rate of 35% 
and the alternative hypothesis of a CR + VGPR rate of >35%. With 80% power to reject the 
null hypothesis if the true CR + VGPR rate was 50% and a one-sided significance level of α 
= 0·10, the required sample size was 48 patients. Patients enrolled at the RP2D in the phase 
1 part of the study were included in the phase 2 part. 
The safety population included all patients who received ≥1 dose of any study drug. 
The DLT-evaluable population included patients in phase 1 who received all cycle 1 doses of 
ixazomib and completed all cycle 1 procedures, or who experienced a DLT during cycle 1. 
The response-evaluable population comprised patients who had received ≥1 dose of study 
drug, had measurable disease at baseline and had ≥1 post-baseline response assessment. 
Safety and efficacy were assessed among all patients, and in phase 2 patients, as well as in 
the modified intent-to-treat (mITT) population, which comprised phase 2 patients plus phase 
1 patients treated at the RP2D. There was no formal statistical testing or analyses; all 
outcomes are reported with descriptive statistical analyses. DOR, PFS and OS were 
assessed using Kaplan–Meier methodology. 
The pharmacokinetic-evaluable population comprised all phase 1 patients with 
sufficient dosing and ixazomib concentration–time data to permit calculation of ixazomib 
plasma pharmacokinetic parameters, which were calculated on days 1 and 11 of cycle 1 
using non-compartmental analysis methods (Phoenix WinNonlin version 6·2, Pharsight, a 
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Patients and disposition 
Sixty-four patients (phase 1, n = 14; phase 2, n = 50) were enrolled between 31 October 
2011 and 12 December 2013. Patient demographics and baseline disease characteristics 
are summarized in Table I: median age was 63·5 years (range 34–82), with 9% of patients 
aged ≥75 years; 52% had International Staging System (ISS) disease stage II or III; 81% 
had normal renal function or mild renal impairment (calculated creatinine clearance >60 
ml/min); and 9% had high-risk cytogenetic abnormalities.  
At the data cut-off (18 October 2016), 60 patients (94%) had discontinued study 
treatment: 20 (31%) to undergo ASCT; 13 (20%) due to an AE; 13 (20%) due to progressive 
disease; 4 (6%) due to withdrawal of consent; 1 (2%) due to unsatisfactory therapeutic 
response; and 9 (14%) for other reasons (patient [n = 4] or investigator [n = 2] decision to 
discontinue treatment but continue follow-up, health complications unrelated to study drug, 
patient removed, lost to follow-up [each n = 1]). Four patients (6%) remained on study 
treatment (phase 1, n = 1; phase 2, n = 3). 
 
DLTs, MTD and RP2D 
In phase 1, 7 patients received ixazomib 3·0 mg and 7 patients received ixazomib 3·7 mg (1 
patient at each dose was not DLT evaluable: at ixazomib 3·7 mg, cycle 1 was not completed; 
at ixazomib 3·0 mg, lenalidomide was taken for 21 days instead of 14 days per protocol). 
There were no DLTs reported at either dose; thus, with no further dose escalation, the MTD 
was 3·7 mg. For estimation of the RP2D, cycle 1 data from 12 evaluable patients were used 
in addition to the available clinical data supporting tolerance over multiple treatment cycles. 
AEs that met DLT criteria or that led to dose modification in cycle 2 and beyond were 
considered when determining the RP2D. Treatment exposure data showed that the median 
relative dose intensity (RDI) of lenalidomide (defined as the dose received divided by the 
dose prescribed, as a percentage) was 73·3% and 97·4% in patients who received ixazomib 
3·7 and 3·0 mg, respectively. The RDI of lenalidomide was impacted by the higher dose of 
ixazomib as a result of overlapping toxicities such as rash, thrombocytopenia and 
gastrointestinal toxicities (http://media.celgene.com/content/uploads/revlimid-pi.pdf, Kumar, 
et al 2014d). Based on this and a review of safety (grade 3/4 AEs, SAEs, all-grade PN and 
treatment discontinuation) and efficacy (CR and VGPR) information, the RP2D was 
determined as 3·0 mg. 
 
Treatment exposure and safety profile 
Among all 64 patients, the median number of treatment cycles received was 9 (range 1–75); 
77% received ≥8 cycles; 39% ≥12 cycles; 30% ≥16 cycles; 14% ≥32 cycles. Forty-five (70%) 
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beyond with single-agent ixazomib maintenance therapy (phase 1, n = 5; phase 2, n = 13; 
mITT, n = 16). Treatment exposure is summarized in Table II. The overall median dose 
intensities (defined as the proportion of planned dose of drug across all treated cycles that 
was actually received) were 92·9%, 94·9% and 94·5% for ixazomib, lenalidomide and 
dexamethasone, respectively.  
Table III summarizes the overall safety profile of twice-weekly ixazomib-Rd. All 
patients except one experienced drug-related AEs, which could have been related to any of 
the treatment drugs; 89% of patients who received single-agent ixazomib maintenance 
experienced new-onset drug-related AEs during maintenance. Drug-related grade 3 AEs 
were reported in 64% of patients, with new-onset events reported in 28% of patients during 
maintenance. There were no drug-related grade 4 AEs. Common drug-related AEs are 
summarized in Table IV; common AEs regardless of attribution are shown in Table SIII. The 
most common drug-related AEs were PN NEC (59%), fatigue (48%), and rashes, eruptions 
and exanthems NEC (high-level term incorporating the preferred terms of rash, macular 
rash, papular rash and maculo-papular rash; 47%); new-onset rates of these drug-related 
AEs during single-agent ixazomib maintenance were 28%, 11% and 17%, respectively. The 
most common drug-related grade 3 events were rashes, eruptions and exanthems NEC 
(13%), hyperglycaemia (8%) and PN NEC (8%); respective new-onset rates during 
maintenance were 6%, 0% and 6%. Changes in FACT/GOG-Ntx score did not follow a 
consistent pattern (data not shown). 
AEs led to dose reduction of any study drug in 66% of all patients, including new-
onset AEs resulting in dose reductions in 33% of patients who received ixazomib 
maintenance (Table III). The most common AEs resulting in dose reductions included PN 
NEC (n = 10, 16%), rashes, eruptions and exanthems NEC (n = 9, 14%), anxiety (n = 7, 
11%), peripheral oedema (n = 5, 8%) and fatigue (n = 4, 6%). Thirty (47%) patients had a 
treatment-emergent SAE, with pneumonia (n = 4, 6%), lung infections (n = 2, 3%), atrial 
fibrillation (n = 2, 3%) and cellulitis (n = 2, 3%) the only events reported in >1 patient. AEs 
leading to discontinuation of study treatment were reported in 13 (20%) patients, with only 
PN NEC (n = 3, 5%) reported in >1 patient. Twelve (19%) patients (all with pre-existing 
cardiac risk factors) reported AEs within the cardiac disorders system organ class, with only 
4 of these patients reporting grade ≥3 AEs, and only 1 discontinuing treatment. Pre-existing 
risk factors for these 4 patients with grade ≥3 AEs included: Patient 1, hyperlipidaemia, 
hypertension, history of coronary artery bypass graft, and sinus bradycardia; Patient 2, 
fatigue, diabetes, hypertension, obstructive sleep apnoea and history of transient ischaemic 
attack; Patient 3 (discontinued treatment), atrial fibrillation, coronary artery disease, diastolic 
dysfunction, dyspnoea, high cholesterol and sinus tachycardia; Patient 4: obesity, 
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patients (8%) had peripheral embolism and thrombosis (grade 3, n = 1). One patient in the 
phase 2 cohort died on study due to cardio-respiratory arrest, which was probably secondary 
to a pulmonary embolism (PE), that was considered related to lenalidomide treatment. 
 
Response and outcomes 
Among all response-evaluable patients, the ORR was 94%, including: CR+VGPR, 68%; CR, 
24% (Table V). In mITT response-evaluable patients, the ORR was 95%, including: CR + 
VGPR, 68%; CR, 27%. A waterfall plot of best M-protein responses (mITT population) is 
shown in Fig 1. Of 6 patients with high-risk cytogenetic abnormalities, 4 achieved a CR 
(duration, 38·5–51·3 months in the 3 patients with available follow-up) and 1 achieved a 
partial response (PR). In the mITT population, the median time to first response was 0·7 
months, and the median time to best response among patients achieving ≥PR, ≥VGPR and 
≥CR was 1·9, 3·4 and 4·2 months, respectively. With 12 of 53 responding patients in the 
mITT population having had progression events, the median DOR was 36·9 months. 
Responses deepened over the course of treatment (Fig 2). Among 18 patients receiving 
ixazomib maintenance therapy, 4 (22%) had improvement in depth of response during this 
phase (1 CR to stringent complete response [sCR]; 1 VGPR to CR; 2 VGPR to nCR). 
A total of 27 patients in the overall study population had an MRD assessment at the 
time of suspected CR. Responses after bone marrow assessment were: CR or sCR, 33%; 
VGPR or nCR, 56%; PR, 7%; and MR, 4%. MRD assessment was successfully performed in 
all 27 patients. Among all 62 response-evaluable patients, 23% had MRD-negative status: 7 
out of 9 patients in CR or sCR (11%) and 7 out of 15 patients in VGPR or nCR (11%). Two 
patients achieved MRD-negative status during the maintenance period. 
Among all 64 patients, 18 (28%) had a PFS event at the time of data cut-off, and 46 
(72%) were censored; patients who proceeded to ASCT were censored at their last 
response assessment. Median PFS was 24·9 months (95% confidence interval [CI], 17·4–
40·5). In the mITT population, 17 (30%) of 57 patients had a PFS event, and median PFS 
was 29·7 months (95% CI, 17·4–not estimable) (Fig 3). With a median follow-up for survival 
of 46·9 months, median OS was not reached in the overall or mITT populations; the 
respective 3-year OS estimates were 91% and 90%. 
 
Stem cell mobilization and engraftment 
Stem cell mobilization was conducted according to individual site protocol and was 
successful, with no failures, for 31 patients after a median of 7 (range 4–13) induction cycles; 
18 (58%) and 13 (42%) patients underwent 1 and 2 apheresis procedures, respectively. The 
most commonly used mobilization regimen was granulocyte colony-stimulating factor (G-
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and G-CSF alone (n = 5, 16%). The median number of harvested CD34+ stem cells was 9·5 
x 106/l (range 4–52 x 106/l). Twenty-four patients then proceeded to early ASCT and 
engraftment kinetics were as expected; median time to neutrophil engraftment (n = 11; 
absolute neutrophil count [ANC] >0.5 x 109/l) was 14 days (range 11–42) and to platelet 
engraftment (n = 13; >20 x 109
 
/l) was 15 days (range 12–111). 
Pharmacokinetics 
Thirteen patients were evaluable for pharmacokinetics. Ixazomib was rapidly absorbed; the 
median first observed time of maximum plasma concentration (Cmax)  was 1 h after dosing on 
both days 1 and 11. At the RP2D, the geometric mean (%CV [coefficient of variation]) Cmax 
was 33·5 (57) ng/ml and 58·7 (32) ng/ml on days 1 and 11, respectively. The corresponding 
values for the area under the plasma concentration versus time curve from 0–72 h post-dose 
(AUC0–72
 
) were 315 (23) h*ng/ml and 1110 (39) h*ng/ml, respectively.  
Discussion 
The RP2D of twice-weekly oral ixazomib plus Rd in patients with NDMM was 3·0 mg. At this 
dose level the ORR was 95%, including 68% CR + VGPR and 27% CR. Responses were 
rapid, deep and durable, deepening over the course treatment. Median PFS was 29·7 
months. The combination had no deleterious effects on the ability to collect stem cells for 
transplant, and engraftment kinetics, where available, did not suggest any adverse effect. 
This was the first study to evaluate twice-weekly ixazomib-Rd for 16 cycles (48 weeks), 
followed by a period of single-agent ixazomib maintenance. The regimen was generally well 
tolerated and long-term therapy was feasible with 28% of patients continuing on therapy 
beyond 16 cycles and proceeding to maintenance. Among all 64 patients, 64% had grade 3 
drug-related AEs; there were no grade 4 drug-related AEs. New-onset drug-related grade 3 
AEs during maintenance therapy with single-agent ixazomib were limited. Pharmacokinetic 
data were similar to other studies suggesting no pharmacokinetic interaction of ixazomib with 
Rd (http://media.celgene.com/content/uploads/revlimid-pi.pdf, Gupta, et al 2017a). 
While the MTD for twice-weekly ixazomib-Rd in patients with NDMM was determined 
to be 3·7 mg, the RP2D was 3·0 mg based on overall tolerability across multiple cycles, 
including an elevated rate of rash with 3·7 mg (Kumar, et al 2014d). Additionally, the RDI of 
lenalidomide was impacted by the higher 3·7 mg dose of ixazomib as a result of overlapping 
toxicities, such as rash, thrombocytopenia and gastrointestinal toxicities 
(http://media.celgene.com/content/uploads/revlimid-pi.pdf, Kumar, et al 2014d). This finding 
is similar to results from a parallel study investigating weekly ixazomib-Rd in patients with 
NDMM in which the lenalidomide RDI was 96% and 84·6% in patients who received 
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2017b, Kumar, et al 2014b). Consequently, 4·0 mg ixazomib was the dose selected for 
phase 3 evaluation of weekly ixazomib-Rd (Gupta, et al 2017b). The RP2D of 3·0 mg 
determined here for twice-weekly ixazomib-Rd is lower than the RP2D of 4·0 mg reported in 
the parallel study investigating weekly ixazomib-Rd in patients with NDMM (Kumar, et al 
2014b). Although the twice-weekly regimen represents a more intensive ixazomib dosing 
schedule compared with weekly dosing, the 21-day cycle used in the present study 
represents a less intensive schedule for Rd, with lenalidomide dosed on days 1–14 
compared with days 1–21 in the weekly ixazomib-Rd study (Kumar, et al 2014b). 
At the RP2D, twice-weekly ixazomib-Rd was associated with a high ORR (95%) in 
patients with NDMM; in particular, the CR + VGPR rate (phase 2 primary endpoint) was 
68%. Responses were rapid in onset and deepened with increasing duration of treatment. 
Approximately one-third of patients discontinued early to undergo ASCT, thereby potentially 
limiting further deepening of responses in these patients. Response rates with twice-weekly 
ixazomib-Rd are similar to those seen with weekly ixazomib-Rd (ORR, 92%; ≥VGPR 58%) 
(Kumar, et al 2014b). Although cross-trial comparisons should be interpreted with caution, 
these response rates and PFS are also similar to those seen with other triplet regimens 
incorporating a proteasome inhibitor and an immunomodulatory drug in NDMM (Durie, et al 
2017, Dytfeld, et al 2014, Kumar, et al 2012, Richardson, et al 2010). Furthermore, 
responses were long-lasting, with a median DOR of 36·9 months. The overall rate of MRD 
negativity in response-evaluable patients who achieved CR, sCR, VGPR or nCR was 23%. 
Other studies in NDMM have reported MRD-negativity rates of around 40% for triplet 
regimens including a proteasome inhibitor and an immunomodulatory agent. In NDMM 
patients treated with KRd, with median follow-up of 13 months and median treatment 
duration of 12 cycles, MRD-negativity was seen in 20/22 patients with CR or suspected CR 
(including nCR) for an MRD-negativity rate in all response-evaluable patients (n = 53) of 
38% (Jakubowiak, et al 2012). In 98 NDMM patients treated with bortezomib in combination 
with thalidomide and dexamethasone with or without cyclophosphamide, with median follow-
up of approximately 65 months, 42 patients (43%) with >PR, including 34 patients (35%) 
with bone-marrow confirmed CR, were MRD-negative (Ludwig, et al 2015). However, any 
comparison of these findings must be interpreted with caution given differences in treatment 
regimen, duration of follow-up, timing of MRD assessment, the numbers of patients tested 
and the sensitivity of the MRD assays used. For example, considering treatment regimen, in 
the Jakubowiak et al study, patients could receive maintenance therapy with KRd for up to 
24 cycles, and in the Ludwig et al study 90% of patients underwent ASCT following initial 
treatment with 4 cycles of bortezomib plus thalidomide and dexamethasone +/- 
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Patients received a median of 9 treatment cycles with twice-weekly ixazomib-Rd, with 
median treatment duration limited by one-third of patients discontinuing to undergo ASCT. 
Nevertheless, 30% and 14% of patients remained on ixazomib therapy for approximately 1 
and 2 years, respectively. Together with the lack of cumulative toxicity seen with long-term 
administration, including the limited new-onset toxicity in patients receiving single-agent 
ixazomib maintenance, these data demonstrate the tolerability and support the feasibility of 
long-term treatment with this regimen. While the role of early versus late transplant requires 
clarification, evidence suggests that prolonged treatment may benefit both transplant-
ineligible and -eligible patients (Attal, et al 2012, Benboubker, et al 2014, Mateos, et al 2012, 
Palumbo, et al 2010).  
Drug-related grade 3 AEs were experienced by 64% of all patients, with no grade 4 
drug-related AEs reported; only 28% of patients proceeding to maintenance reported new-
onset drug-related grade 3 AEs during maintenance with single-agent ixazomib. AEs led to 
dose reductions (of any agent) or discontinuation in 66% and 20% of patients, respectively. 
AE rates reported here appear similar to those seen in the parallel study of weekly ixazomib-
Rd in patients with NDMM, but dose reductions and discontinuations due to AEs were lower 
with weekly ixazomib dosing (57% and 8%, respectively) (Kumar, et al 2014b). The AE 
profile reported here was largely expected based on clinical experience with each drug in 
this triplet regimen. The most common drug-related AEs were PN NEC (high-level term), 
fatigue, rashes, eruptions and exanthems NEC (high-level term) and nausea; the majority of 
these AEs were grade 1 or 2.  
Rashes, eruptions and exanthems NEC were seen in a substantial number of 
patients, but were mainly low grade, were not reported as DLTs and proved manageable 
with dose modifications (including reductions or holding of either lenalidomide or ixazomib, 
whichever was the causative agent) and oral or topical antihistamines, as required. The 
occurrence of rash events probably represents an overlapping effect of lenalidomide 
(Tinsley, et al 2015) and ixazomib (Gupta, et al 2016b, Kumar, et al 2014d, Richardson, et al 
2014). The rate of 47% for drug-related, any-grade rashes, eruptions and exanthems 
reported here is higher than the rate of 29% reported for this high-level term in the parallel 
phase 1/2 study investigating weekly ixazomib-Rd in patients with NDMM (Takeda, 
unpublished data, February 2017). It is difficult to put these data into context with safety 
findings for other proteasome inhibitors due to differences in how rash events have been 
reported (in aggregate, or as individual preferred terms). For example, a phase 1/2 study of 
bortezomib-Rd in patients with NDMM reported the incidence of all-grade and grade 3 
rash/desquamation as 36% and 2%, respectively (Richardson, et al 2010). 
Drug-related PN NEC was reported in 59% of patients but was grade 3 in 8%. These 
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(all grades, 38%; grade ≥3, 6%) (Kumar, et al 2014b). PN is an AE of clinical interest with 
respect to some proteasome inhibitors, and these findings should be viewed in the context of 
available data for other agents. Phase 3 evaluation of bortezomib-Rd in patients with NDMM 
without intent for immediate ASCT reported 33% of patients with treatment-related grade ≥3 
neurological events (Durie, et al 2017). In a phase 2 study of bortezomib-Rd in patients with 
NDMM, grade 1/2 PN occurred in 55% of patients, and grade ≥3 neuropathy in 17% of 
patients (Kumar, et al 2012). Phase 1/2 evaluation of bortezomib-Rd in patients with NDMM 
reported sensory neuropathy in 80% of patients (2% grade 3) and motor neuropathy in 18% 
of patients (2% grade 3) (Richardson, et al 2010). A phase 1/2 study of KRd in NDMM 
reported treatment-emergent PN (all grade ≤2) during induction (cycles 1–8) in 23% of 
patients; during maintenance, PN remained limited (11%; all grade ≤2); most neuropathic 
events were attributed to lenalidomide (Jakubowiak, et al 2012). Limited additional PN was 
seen with ixazomib-Rd versus placebo-Rd in the TOURMALINE-MM1 study in RRMM, 
consistent with lenalidomide being associated with neuropathic events (Moreau, et al 2016). 
Awareness of cardiovascular toxicity associated with proteasome inhibitors is 
increasing (Koulaouzidis and Lyon 2017). Integrated nonclinical and clinical risk assessment 
has previously reported no clinically meaningful effects of ixazomib on QTc or heart rate 
(Gupta, et al 2015b). The incidence of cardiovascular AEs in patients with no pre-existing 
cardiac risk factors was limited in the present study and included 2 patients (3%) with atrial 
fibrillation reported as a treatment-emergent SAE. Twelve patients (19%) reported AEs 
within the cardiac disorders system organ class; however, these patients all had pre-existing 
cardiac risk factors. Cardiovascular AEs, including heart failure (Roussel, et al 2016), have 
previously been reported with KRd in NDMM patients . Cardiovascular toxicities have also 
been reported with bortezomib-Rd in NDMM patients , including: treatment-related cardiac 
arrhythmia (5%) and general cardiac events (21%) (Durie, et al 2017), and QTc interval 




cardiac toxicities under warnings and precautions reflective of these safety concerns, but this 
is not noted in the ixazomib prescribing information (https://www.ninlaro.com/prescribing-
information.pdf; http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/003844/WC500217620.pdf) and our data support no such 
safety concerns with ixazomib-based combinations.  
We demonstrate that twice-weekly ixazomib-Rd offers substantial activity and 
promising outcomes in NDMM patients  but appears to be associated with a somewhat 
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weekly dosing is potentially warranted to define a subset of patients who are able to tolerate, 
and benefit from, more intensive therapy.  
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Table I. Patient demographics and baseline disease characteristics among all patients, by study phase, and in the mITT population. 
 Phase 1  
n = 14 
Phase 2  
n = 50 
mITT  
n = 57 
Total  
N = 64 
Median age, years (range) 63 (42–78) 63.5 (34–82) 64 (34–82) 63.5 (34–82) 
Male / female, n (%) 9 (64) / 5 (36) 31 (62) / 19 (38) 36 (63) / 21 (37) 40 (63) / 24 (38) 
Race, n (%)     
   White 12 (86) 42 (84) 47 (82) 54 (84) 
   Black or African American 1 (7) 7 (14) 8 (14) 8 (13) 
   Other / not reported 1 (7) / 0 0 / 1 (2) 1 (2) / 1 (2) 1 (2) / 1 (2) 
ECOG performance status, n (%)     
   0 8 (57) 27 (54) 30 (53) 35 (55) 
   1 5 (36) 21 (42) 25 (44) 26 (41) 
   2 1 (7) 2 (4) 2 (4) 3 (5) 
ISS disease stage at diagnosis, n (%)     
   I 8 (57) 23 (46) 25 (44) 31 (48) 
   II 5 (36) 17 (34) 21 (37) 22 (34) 
   III 1 (7) 10 (20) 11 (19) 11 (17) 
MM disease subtype, n (%)     
   IgG 7 (50) 31 (62) 34 (60) 38 (59) 
   IgA 3 (21) 13 (26) 15 (26) 16 (25) 
   Light chain 3 (21) 4 (8) 6 (11) 7 (11) 
   Biclonal 1 (7) 1 (2) 1 (2) 2 (3) 
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Creatinine clearance, ml/min, median (range) 70·6 (31·68–140·61) 74·9 (40·94–180·50) 74·6 (31·68–180·50) 74·6 (31·68–180·50) 
Cytogenetic testing,* n (%)     
   Conventional/karyotype 0 2 (4) 2 (4) 2 (3) 
   Molecular/FISH 12 (86) 14 (28) 20 (35) 26 (41) 
   Both 2 (14) 34 (68) 35 (61) 36 (56) 
Patients with cytogenetic abnormality, n (%) 11 (79) 31 (62) 36 (63) 42 (66) 
Patients with high-risk cytogenetics,† 1 (7)  n (%) 5 (10) 6 (11) 6 (9) 
   Monosomy 17 / del17p  0 3 (6) 3 (5) 3 (5) 
   t(4;14) 1 (7) 2 (4) 3 (5) 3 (5) 
ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in-situ hybridisation; Ig, immunoglobulin; ISS, International Staging System; mITT, modified 
intent to treat; MM, multiple myeloma. 
*Cytogenetics were evaluated locally.  
†
 
High-risk cytogenetics included del17, t(4;14), t(14;16). 
 
 
Table II. Treatment exposure. 
 Phase 1  
n = 14 
Phase 2  
n = 50 
mITT  
n = 57 
Patients who 
did not proceed 
to ASCT  




n = 18 
All  
N = 64 
Cycles received, median (range) 10·5 (1–75) 8·5 (1–61) 9 (1–75) 13 (1–75) 31·5 (17–75) 9 (1–75) 
Cycles received, n (%)       
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   ≥12 6 (43) 19 (38) 23 (40) 22 (54) 18 (100) 25 (39) 
   ≥16 5 (36) 14 (28) 17 (30) 18 (44) 18 (100) 19 (30) 
   ≥32 2 (14) 7 (14) 9 (16) 9 (22) 9 (50) 9 (14) 
Median relative dose intensity*, %       
   Ixazomib 88·8 93·8 93·8 89·8 88·3 92·9 
   Lenalidomide 73·5 97·4 97·1 89·4 91·4 94·9 
   Dexamethasone 93·7 94·5 93·8 95·3 93·2 94·5 
Patients remaining on treatment, 
n (%) 
1 (7) 3 (6) 4 (7) 4 (10) 4 (22) 4 (6) 
ASCT, autologous stem cell transplantation; mITT, modified intent to treat.  
*Dose received as a percentage of the total planned dose over all treated cycles. 
 
 
Table III. Overall safety profile of twice-weekly ixazomib plus lenalidomide and dexamethasone. 
AE, n (%) 
Phase 1  
n = 14 
Phase 2  
n = 50 
mITT  




n = 18 
Total  
N = 64 
Any AE 14 (100) 50 (100) 57 (100) 16 (89) 64 (100) 
   Any drug-related AE 14 (100) 49 (98) 56 (98) 16 (89) 63 (98) 
Any grade ≥3 AE 11 (79) 37 (74) 43 (75) 8 (44) 48 (75) 
   Any drug-related grade ≥ 3 AE 10 (71) 31 (62) 36 (63) 5 (28) 41 (64) 
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AE, adverse event; mITT, modified intent to treat; SAE, serious adverse event. 
*New-onset AEs during cycle ≥17. 
 
Table IV. Drug-related* AEs reported at any grade in ≥15% of the total population and/or at grade 3 in ≥5% of the total population (no 
drug-related grade 4 AEs were reported). 
 
Phase 1, n = 14 Phase 2, n = 50 
Patients who received 
mITT, n = 57 maintenance,† n = 18 Total, N = 64 











3 All-grade Grade 3 All-grade Grade 3 
PN NEC 10 (71) ‡ 2 (14) 28 (56) 3 (6) 33 (58) 4 (7) 5 (28) 1 (6) 38 (59) 5 (8) 
Fatigue 9 (64) 1 (7) 22 (44) 1 (2) 27 (47) 2 (4) 2 (11) 0 31 (48) 2 (3) 




3 (21) 23 (46) 5 (10) 25 (44) 6 (11) 3 (17) 1 (6) 30 (47) 8 (13) 
Nausea 5 (36) 0 17 (34) 1 (2) 19 (33) 1 (2) 6 (33) 1 (6) 22 (34) 1 (2) 
Diarrhoea 5 (36) 0 15 (30) 1 (2) 18 (32) 1 (2) 5 (28) 1 (6) 20 (31) 1 (2) 
Peripheral oedema 7 (50) 1 (7) 13 (26) 1 (2) 17 (30) 2 (4) 2 (11) 0 20 (31) 2 (3) 
Dysgeusia 3 (21) 0 17 (34) 0 18 (32) 0 0 0 20 (31) 0 
Insomnia 6 (43) 1 (7) 13 (26) 0 15 (26) 0 0 0 19 (30) 1 (2) 
   Any drug-related SAE 5 (36) 16 (32) 19 (33) 2 (11) 21 (33) 
AE resulting in any study drug 
dose reduction 
11 (79) 31 (62) 37 (65) 6 (33) 42 (66) 
AE resulting in discontinuation 3 (21) 10 (20) 11 (19) 3 (17) 13 (20) 
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Constipation 4 (29) 0 14 (28) 0 15 (26) 0 0 0 18 (28) 0 
Dizziness 2 (14) 0 12 (24) 2 (4) 14 (25) 2 (4) 1 (6) 0 14 (22) 2 (3) 
Vomiting 3 (21) 0 8 (16) 1 (2) 9 (16) 1 (2) 3 (17) 1 (6) 11 (17) 1 (2) 
Anxiety 3 (21) 0 9 (18) 1 (2) 11 (19) 1 (2) 0 0 12 (19) 1 (2) 
Muscle spasms  3 (21) 0 9 (18) 0 11 (19) 0 0 0 12 (19) 0 
Muscular weakness 3 (21) 0 7 (14) 1 (2) 9 (16) 1 (2) 2 (11) 1 (6) 10 (16) 1 (2) 
Hyperglycaemia 4 (29) 3 (21) 4 (8) 2 (4) 8 (14) 5 (9) 2 (11) 0 8 (13) 5 (8) 
Hyponatraemia  1 (7) 1 (7) 3 (6) 3 (6) 3 (5) 3 (5) 0 0 4 (6) 4 (6) 
ALT increased 2 (14) 2 (14) 4 (8) 1 (2) 4 (7) 1 (2) 1 (6) 0 6 (9) 3 (5) 
Pneumonia 1 (7) 1 (7) 4 (8) 3 (6) 5 (9) 4 (7) 0 0 5 (8) 4 (6) 
Neutrophil count decreased 0 0 3 (6) 3 (6) 3 (5) 3 (5) 1 (6) 1 (6) 3 (5) 3 (5) 
Neutropenia 1 (7) 1 (7) 4 (8) 2 (4) 5 (9) 3 (5) 0 0 5 (8) 3 (5) 
Thrombocytopenia 2 (14) 2 (14) 2 (4) 1 (2) 3 (5) 2 (4) 0 0 4 (6) 3 (5) 
AE, adverse event; ALT, alanine aminotransferase; mITT, modified intent to treat; 
*Drug-related defined as related to any drug in the combination.  
NEC, not elsewhere classified; PN, peripheral neuropathy. 
†New-onset AEs during cycle ≥17.  
‡High-level term, includes PN and peripheral sensory neuropathy.  
#
 
High-level term, includes rash, macular rash, papular rash and maculo-papular rash. 
Table V. Confirmed best response to treatment among response-evaluable patients, by study phase and overall. 
Response rate, n (%) 
[95 % CI] 
Phase 1 
n = 13 
Phase 2 
n = 49 
mITT 
n = 56 
Patients who entered the maintenance period  
n = 18 
Total 
N = 62 
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[64, 100] [83, 99] [85, 99] [73, 100] [84, 98] 




















         sCR 0 11 (22) 11 (20) 5 (28) 11 (18) 
      VGPR 9 (69) 18 (37) 23 (41) 8 (44) 27 (44) 
         nCR 2 (15) 5 (10) 6 (11) 4 (22) 7 (11) 
   PR 2 (15) 14 (29) 15 (27) 1 (6) 16 (26) 
MR 1 (8) 3 (6) 3 (5) 1 (6) 4 (6) 
Stable disease 0 0 0 0 0 
Progressive disease 0 0 0 0 0 
CI, confidence interval; CR, complete response; mITT, modified intent to treat; MR, minimal response; nCR, near complete response; ORR, 
overall response rate; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.  
62 of 64 patients were evaluable for response (2 patients did not have post-baseline response assessments; thus were not evaluable). Data 
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FIGURES 
Fig 1. Waterfall plot of best M-protein response, among response-evaluable patients treated 
at the recommended phase 2 dose (modified intent-to-treat population). 
 
Fig 2. Increasing depth of response with increasing duration of therapy in response-
evaluable patients treated at the recommended phase 2 dose (modified intent-to-treat 
population). CR, complete response; ORR, overall response rate; PR, partial response; sCR, 
stringent complete response; VGPR, very good partial response. 
  
Fig 3. Kaplan-Meier analysis of progression-free survival in the modified intent-to-






































































































After 12 cycles (n = 20)
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